MeTa, Solwezi 27 August,2013.  A branded- name drug product is originally discovered and developed by a pharmaceutical company.  Branded-name drugs.

Slides:



Advertisements
Similar presentations
الرابطة الدولية لمكافحة المواد الطبيّة المزورة a WHO initiative to combat counterfeit medical products Dr V. Reggi - World Health Organization.
Advertisements

JFDA & HAI Workshop Towards equitable and affordable medicine prices policy in Jordan 4-5 December 2007 Strategies to aid market entry and competition.
Ranbaxy Laboratories Limited Differential Pricing & Financing of Essential Drugs Experience with Generic drugs Cecile H Miles Head of Western Europe Division.
Copyright of the Health Sciences Authority 2007 ASEAN-China Conference on Combating Counterfeit Medical Products Jakarta, November 2007 Singapore.
IMPACT Principles and Elements for National Legislation Presented by: Chair, Working Group on Regulatory Implementation, on behalf of Chair, Working Group.
International Medical Products Anti-CounterfeitingTaskforce INSPECTOR OF DRUGS NATIONAL DRUG AUTHORITY- UGANDA.
Anti- Piracy Unit (APU) REPUBLIC OF MAURITIUS 1. MAURITIUS 2.
International Medical Products Anti-CounterfeitingTaskforce.
First ASEAN-China Conference on Combating Counterfeit Medical Products Jakarta November 2007 CHOO CHEOK HANG DEPARTMENT OF PHARMACEUTICAL SERVICES.
DG Enterprise and Industry Approach on Combating Counterfeit Medicines Council of Europe Conference “Europe against Counterfeit Medicines” Session: Key.
Tom Kubic Executive Director Pharmaceutical Security Institute World Bank Washington 10 March 2005 The Spreading Plague of Counterfeiting.
U.S. Drug Supply Chain Integrity: Protecting Patient Safety CDR Connie Jung, PharmD, PhD LCDR Eleni Anagnostiadis, RPh Office of Drug Security, Integrity,
- 0 - Medicines manufactured under these conditions What do you want your Patients to receive??
Counterfeit Medicines and Fight against Counterfeit Medicines.
Developed by Cool Pictures & MultiMedia PresentationsCopyright © 2007 by South-Western, a division of Thomson Learning. All rights reserved. Product Adaptation.
Copyright Atomic Dog Publishing, 2002 Products and Services: Branding Decisions in International Markets Dana-Nicoleta Lascu Chapter 9.
Strengthening the Protection of Intellectual and Industrial Property Rights Deputy Manager Jan Hylleberg The Danish Association of the Pharmaceutical Industry.
January 16, 2010 Monica Robinson Green, PharmD, BCPS.
Rational Use of Injections within National Drug Policies World health organisation Essential Drugs and Medicines Policy Safe Injection Global Network Cairo.
“Using Competition Law to Promote Access to Health Technologies” Access to Innovation: Making Generic Versions of Newer ARVs Affordable 24 July 2014 Melbourne,
What is a Generic Medication?. The World Health Organization Definition of a Generic Medication A generic drug is a pharmaceutical product, usually intended.
The Korus FTA Will Lead to Higher Drug Prices in Korea
1 Promoting Safe Medicine With Track and Trace Systems SRC Technologies, Inc.
Drug Pricing in Canada Victoria Brown, Anureet Sohi, Lisa Weger SPHA 511.
Generic Substitution Principles in Practice Copyright © – Academy of Managed Care Pharmacy (AMCP)Slide 1.
A very short introduction to patents & access to medicines.
What You Want to Know About Generic Drugs Generic Drugs: Safe. Effective. FDA-Approved.
Pharmaceutical Manufacturers Association PMA Status of National Production Capacity of Generic Medicines – Private Sector Perspective Emmanuel Mujuru,
Restrictions on exports of medicine: irrational public policy, backdoor efforts to marginalize compulsory licensing, or Northern protectionism? James Love.
John Anderson Chairman The Global Anti-Counterfeiting Group.
Quality Control Approaches for Essential Medicines “Good Intentions – Bad Drugs” The World Bank March 10, 2005.
1 Stop Stock-outs! Access to Medicines for All! anti-counterfeiting initiatives and other access barriers Christa Cepuch OSI AEM Initiative – CS Role and.
Veiovis LifeSciences Pvt Ltd
Pharmaceutical system strengthening – Is there a need for a new paradigm? Andreas Seiter The World Bank ICIUM 2011, Antalya 1.
Overviews of the Drug Distribution System & Barriers to Opioid Availability Dr. Bishnu Dutta Paudel International Pain Policy Fellowship Training Program.
Paula Munderi Department of Essential Drugs and Medicines Policy World Health Organization Access to essential medicines for HIV/AIDS - update on WHO activities.
Do Patents Make HIV/AIDS Medication Inaccessible to Patients in Sub-Saharan Africa? Abstract There has been debate surrounding the issue of patents and.
ACCESS TO MEDICINES - POLICY AND ISSUES
UNCTAD/CD-TFT 1 Exclusive Rights and Public Access – Flexibilities in International Agreements and Development Objectives The Public Health Example 21.
1 Department of Medicines Policy and Standards, Health Technology and Pharmaceuticals WHO’s Role in Assuring the Quality Safety and Efficacy of Medicines:
Zambia’s Porous Borders & the Influx of Medicines.
Social Pharmacy Lecture no. 6 Rational use of drugs Dr. Padma GM Rao
The essence of global pharmaceutical marketing. Definitions of marketing ‘Marketing is the management process that identifies, anticipates and satisfies.
Development and Implementation of Good Pharmacy Practice Standards in Developing Countries Author: Frokjaer B, International Pharmaceutical Federation.
Managing Procurement and Logistics of HIV/AIDS Drugs and Related Supplies By Yvonne Nkrumah Legal Counsel, Ghana Food and Drugs Board.
Medicines Transparency Alliance16/12/ MeTA Uganda: Promotion Nazeem Mohamed MeTA Council Co-Chair.
Quality & Safety of Generic Drugs in the World Market World Bank Conference “Good Intentions – Bad Drugs” March 10, 2005 Washington, D.C. Christine Simmon.
INTRODUCTION AND OBJECTIVES LEGAL ASPECTS AND SOCIO-ECONOMIC IMPLICATIONS REGARDING DRUG COUNTERFEITING CIOBANU CONSTANTIN, CORCIOVĂ ANDREIA Faculty of.
By: Drew Perry. Counterfeit pharmaceutical drugs are fraudulently produced or mislabeled medicines purchased by consumers who believe them to be legitimate.
GMP- A Regulatory Perspective. Regulatory Perspective in entering Global Pharma Markets.
CH-ZWA jsmGB IKEA Industry Globalization Potential James Oldroyd Kellogg Graduate School of Management Northwestern University
Issues related to poor IP protection in EMs: Pharmaceutical Example Rob May Commercial Director, Janssen, EMEA Emerging Markets.
Top 9 benefits of generic pharmacy Published by :
Regulation of Generic Animal Drugs in the United States
Overview: The South African IP Policy Review 13 September 2012 MacDonald Netshitenzhe: Chief Director- Policy and Legislation.
GB590 Corporate Social Responsibility Prof. Ray Kalinski By Willette Marchany Rivera December 13, 2010.
1 Special mechanism for the importation of pharmaceutical products under the TRIPS Agreement Carlos M. Correa.
Human Rights and Access to Medicines Sean Flynn AU, Washington College of Law Abuja, Nigeria, November 2008.
ANTI COUNTERFEIT FROM COMMUNITY PERSPECTIVE -Estimates indicates 30% of drugs in Kenyan market are fake. -40 billion lost every year due to counterfeit.
The Law of the KR «On making amendments and changes to certain legislative acts of the KR» 4 th MeTA Forum in the Kyrgyz Republic Bishkek, December 8,
iHEA 9th World Congress Sydney, July 8, 2013
Taxonomy of Strategies
ACCESS TO QUALITY MEDICINES IN THE REGION-COUNTERFEITING PROBLEMS
BASICS IN PHARMA.
Intellectual Property Protection and Access to Medicines
The Problem of Substandard Medicines in Developing Countries
CHAWLA MEDICOS Present’s Branded v/s Generic medicine
Quality Problems with Antimalarials
Fight Against Falsified medicines
Counterfeiting and Intellectual property theft in Medicines World Bank Symposium March 10, 2005 Washington DC Frederick Razzaghi Director of Technical.
Presentation transcript:

MeTa, Solwezi 27 August,2013

 A branded- name drug product is originally discovered and developed by a pharmaceutical company.  Branded-name drugs are marketed exclusively by the innovator company.  A branded drug is an intellectual property,therefore it is patented. A Patent may have duration of up to 20 years.

 Branded-name drugs are labelled under Trade/Proprietory names and the manufactures name.  Coartem(Artemether/Lumefantrine)-Novartis  Viagra(Sildenafil Citrate)-Pfizer

 Generic drugs are copies of branded-name drugs with the same high quality,purity,strenghth and intended use as branded-name drugs.  The term Generic drug also referrers to any drug marketed under its chemical name without advertising.

 Generic drugs are labelled under an adopted name(non-proprietary name) and the manufacturers name.  Generic drugs are manufactured and Sold by other pharmaceutical companies, after the patent for the innovator company has expired.

 Contain the same active ingredient.  Have the same strength  Same dosage form(tablet, suspension or injection).  Same route of administration(oral, injectable)  Both attain the same blood concentration after intake(Bioequivalent).

 Branded-name and Generic drugs have to pass through the same quality standards required by the drug regulation authority.

Inactive ingredients Shape Colour Taste Preservatives Packaging labelling

1.Advantages  Easily accessible.  Affordable.  Inc  increase access to health care for the majority. 2.Disadvantages  Not all branded name drugs have generic counterparts

 Some patients are brand-name specific

 Substandard medicines are products whose composition and ingredients does not meet correct scientific specifications and which are consequently ineffective and often dangerous to the patient.  Causes of Substandard medicines  Negligence during manufacture, distribution and storage.

 Human error  Insufficient human resource  Financial resources  Counterfeiting

 Counterfeit medicines are Substandard medicines that are deliberately and fraudulently mislabelled with respect to identity and/or source.  All counterfeit medicines are substandard, but not all substandard medicines are counterfeit.  Types of counterfeit medicines;

 Products with correct active ingredient but fake packaging.  Products with wrong ingredients(active/inactive).  Products without active ingredients.  Products with insufficient active ingredients.  Counterfeiting can apply to both Branded- name and Generic medicines.

 Poverty-high prices of medicines and high price differentials between identical.  High demand.  Low production costs.  Absence of deterrent legislation.

 In developed countries:  New drugs  Expensive lifestyle medicines- hormones,steroids,antihistamines  In developing countries;  Those that are used to treat life threatening conditions such as Malaria,Tuberculosis and HIV/AIDs.

 The internet is also becoming one of the major sources of counterfeit medicines.  Of all drugs in the world,Viagra is the most counterfeited medicine.

 Treatment failure.  Drug resistance-resulting from drug resistant pathogens.  Most cases leading to death.

 Counterfeit medicines make up 10% of the global medicines market and are present both in developed and developing countries.  25% of the medicines consumed in poor countries are counterfeit or substandard.  Global earnings from counterfeit medicines is over $32 billion dollars annualy.

 Where ;  Drug regulation and control is weak.  Enforcement scarcity  Supply of medicines is erratic  Drug markets are unregulated  Medicine prices are unaffordable  The countries include those in Africa, south America and south east Asia.

 Lack of regulation and enforcement- smuggling and illegal importation.  increasing national and international trade in alternative medicines/herbal medicines- herbal medicines are highly unregulated  Some policy makers believe drug regulation presents unnecessary barrier to trade and should be reduced to minimum.

 Medicines exported from industrialised countries are not regulated to the same level as those consumed domestically.

 Establishing competent national drug authorities with necessary human and other resources to control the manufacture,importation,distribution and sale of medicines.  Government to develop strategies to reduce corruption and criminal activity and promote intersectoral cooperation between regulatory

authorities, the police,customes services and the judiciary to effectively control the drug market and enforce regulation.  Increasing public awareness.  Harmonizing measures between trading countries.  Pre-qualification-Assessing products and manufactures and,providing a list of those

meeting WHO guidelines to countries and procurement agencies, in order to promote procurement of quality medicines.